Emerging research suggest this peptide, a dual agonist targeting both GLP-1 and another hormone, could represent a notable advancement for weight management . Preliminary clinical tests have shown considerable losses in abdominal mass , conceivably surpassing existing obesity therapies . Despite this, additional assessment is needed to fully determ